Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.

Authors	Matthew R Schuelke, Hamid Bassiri, Edward M Behrens, Scott Canna, Colleen Croy, Amanda DiNofia, Kandace Gollomp, Stephan Grupp, Michele Lambert, Arathi Lambrix, Shannon L Maude, Regina Myers, Haley Newman, Whitney Petrosa, Alix Seif, Kathleen E Sullivan, David T Teachey, Caroline Diorio
Journal	Blood advances (Blood Adv) Vol. 7 Issue 18 Pg. 5603-5607 (09 26 2023) ISSN: 2473-9537 [Electronic] United States
PMID	37721859 (Publication Type: Research Support, Non-U.S. Gov't, Letter)
Chemical References	Emapalumab Antibodies, Monoclonal Antibodies, Neutralizing
Topics	Humans Child Cytokine Release Syndrome (drug therapy, etiology) Antibodies, Monoclonal (adverse effects) Antibodies, Neutralizing

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!